🔗 Share this article

Given that the United States undertakes sweeping revisions to its vaccine schedules, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by questioning COVID-19 vaccines during the global health crisis and has zeroed in on potential deaths after Covid immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Changes to Pediatric Vaccine Schedule

Health officials were set to announce sweeping changes to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of alignment with many the international standard with little proof for improved outcomes. This reveal has been delayed until the coming year.

In place of the director of the vaccine center, Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

A Shift at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad strengthen their influence at the agency – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric shot schedules in the US so as to align more like Denmark's approach, a society with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

To date statements, she has kept her attention on immunizations – usually the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent experience in medication creation, oversight or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, remarked a neurologist and psychiatrist. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in pharmaceutical oversight.”

Past heads of the center would “grasp regulatory frameworks and the research of drug development”, said Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an immense portfolio at the FDA, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic program authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and more, and every single one must be managed,” she said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a significant management component to the position, which manages in excess of 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” Woodcock concluded.

Response and Disputed Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “concerns are based on incorrect presumptions”.

“This background aligns with the duties of her position,” the representative explained, noting the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg inherits the agency head's controversial fast-track approval initiative, a controversial expedited medication authorization process that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who makes the choices?” Dr. Howard said. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent oversight of all drugs, with the exception of immunizations.”

Established History on Immunizations

Concerning vaccines, Høeg has a more documented, if troubling, track record, critics observe. She published a analysis using unverified public submissions to estimate the frequency of myocarditis after COVID-19 immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to imply Covid vaccines are more dangerous than they are.

Part of her “wish list” for the current federal leadership featured revising regulations for recently developed shots and discontinuing “unnecessary” vaccines, she stated following the vote on a audio program. At the agency, Dr. Høeg has according to sources floated the idea of barring teenage boys from receiving COVID-19 vaccines.

“She’s an complete dogmatist who commences with her beliefs and reverse-engineers to retrofit the data in a highly misleading, untruthful way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|